作者
Peter G Pappas, Coleman MF Rotstein, Robert F Betts, Marcio Nucci, Deepak Talwar, Jan J De Waele, Jose A Vazquez, Bertrand F Dupont, David L Horn, Luis Ostrosky-Zeichner, Annette C Reboli, Byungse Suh, Raghunadharao Digumarti, Chunzhang Wu, Laura L Kovanda, Leah J Arnold, Donald N Buell
发表日期
2007/10/1
期刊
Clinical infectious diseases
卷号
45
期号
7
页码范围
883-893
出版商
The University of Chicago Press
简介
Background. Invasive candidiasis is an important cause of morbidity and mortality among patients with health care–associated infection. The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis.
Methods. This was an international, randomized, double-blind trial comparing micafungin (100 mg daily) and micafungin (150 mg daily) with a standard dosage of caspofungin (70 mg followed by 50 mg daily) in adults with candidemia and other forms of invasive candidiasis. The primary end point was treatment success, defined as clinical and mycological success at the end of blinded intravenous therapy.
Results. A total of 595 patients were randomized to one the treatment groups and received at least 1 dose of …
引用总数
学术搜索中的文章
PG Pappas, CMF Rotstein, RF Betts, M Nucci, D Talwar… - Clinical infectious diseases, 2007